This phase I trial evaluates effectiveness, safety and tolerability of the targeted therapy (AMG 397) for the treatment of patients with Multiple Myeloma, Non-Hodgkin Lymphoma or Acute Myeloid Leukaemia.
This trial is treating patients with Multiple Myeloma, Acute Myeloid Leukaemia and Non-Hodgkin Lymphoma.
This is a systemic therapy.
You may be able to join this trial if:
- You are able to swallow medication by mouth.
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
- You have had treatment, but your cancer has come back.
You may be excluded from this trial if:
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies
This study aims to assess the effectiveness, safety, tolerability and optimal dose regime for the targeted therapy AMG 397 to treat patients with recurrent Multiple Myeloma, Non-Hodgkin Lymphoma or Acute Myeloid Leukaemia. Patients eligible to participate in this trial will receive AMG 397 two consecutive doses per week over a 28 day cycle.
Not Recruiting Hospitals Read More